Abstract
SummaryACE inhibitors (ACEIs) are commonly prescribed for hypertension, a global risk factor for cardiovascular disease. Their primary side effect is a dry cough which affects 5-35% of users. As clinical guidelines recommend switching those experiencing cough to an angiotensin-II receptor blocker, we have used this switch as a proxy for ACEI-induced cough. Through a two-stage multi-ancestry genome-wide association study, including up to 7,030 cases and 39,921 controls, we identify five independent genome-wide significant associations implicating six protein-coding genes, including INHBC, KCNIP4, NTSR1 and PREP which encode proteins involved in the nervous system. We also observe genetic overlap between ACEI-induced cough and chronic dry cough through genetic correlation and phenome-wide association studies. In line with existing hypotheses, our findings suggest a neurological basis for the pathology of ACEI-induced cough, particularly the role of proinflammatory mediators in sensory airway sensitivity and cough reflex modulation, and shared biological mechanisms with chronic dry cough.
Publisher
Cold Spring Harbor Laboratory
Reference88 articles.
1. National Institute for Health and Care Excellence (2021). Hypertension: Angiotensin-converting enzyme inhibitors.
2. NHS Digital (2018). Prescriptions Dispensed in the Community - Statistics for England, 2007-2017. Prescr. Dispens. Community. https://digital.nhs.uk/data-and-information/publications/statistical/prescriptions-dispensed-in-the-community/prescriptions-dispensed-in-the-community-england---2007---2017.
3. Comprehension of Top 200 Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice;Pharmacy,2018
4. Herman, L.L. , Padala, S.A. , Ahmed, I. , and Bashir, K. (2021). Angiotensin Converting Enzyme Inhibitors (ACEI). In StatPearls (StatPearls Publishing).
5. Angiotensin-Converting Enzyme Inhibitor-Induced Cough